A recent scientific follow-up study of patients who underwent autologous stem cell therapy for amyotrophic lateral sclerosis, or ‘s disease, has proved the effectiveness of the therapy. Returning Hope, in Thailand, is one of the first Asian health care providers to arrange for this type of stem cell treatment.
The follow up study was conducted by a team from Akay Hospital, GATA, the University of Marmara, and the Sila Neurorehabilitation Center. It followed 13 patients for one year after stem cell treatment for ALS.
Participants in the study had the following outcomes:
- Nine of thirteen participants had significant improvement, proven by electroneuromyography.
- Three patients died from conditions unrelated to ALS, including lung infection and myocardial infarction
- One patient’s condition was stable, with no improvement or decline
Previous treatments for ALS included growth hormone therapy, which was recently proven ineffective.
Brian Dardzinski, Returning Hope’s CEO, believes the study’s results were inevitable. “We have been partnering with treatment facilities to provide stem cell therapy for ALS for some time now. Our patients have had substantial improvement”.
“It was only a matter of time before a widely publicized study proving our results became available. But we are very pleased that more patients may have the opportunity to undergo stem cell therapy for ALS, due to the new study”, Mr Dardzinski continued.
About Returning Hope
Returning Hope is an online portal and facilitator, providing information and assistance to patients looking for adult stem cell treatment. Most of the procedures that Returning Hope facilitates involve autologous transplants – stem cells are harvested from a patient’s own fat in a quick, simple bedside procedure and re-implanted. Autologous adult stem cell therapy can give hope to patients who were previously told their conditions were untreatable, including stroke, autism, ALS, diabetes, cerebral palsy, Parkinson’s and multiple sclerosis.